Oil prices hold sharp losses with focus on secondary India tariffs
MAINZ, Germany - On Monday, BioNTech SE (NASDAQ:BNTX) reported second quarter 2025 revenue that doubled YoY to €260.8 million, significantly exceeding analyst estimates of €137.9 million.
The company’s shares rose 2.45% in pre-market trading after the quarterly release.
The biotechnology firm posted a net loss of €386.6 million or -€1.60 per share, slightly worse than the expected -€1.41 per share.
The revenue beat comes as BioNTech continues its strategic pivot from COVID-19 vaccines toward oncology, highlighted by a transformative collaboration with Bristol Myers (NYSE:BMY) Squibb for its bispecific antibody candidate BNT327. The deal, which includes a $1.5 billion upfront payment expected in the third quarter, plus $2 billion in non-contingent payments through 2028 and up to $7.6 billion in potential milestone payments, significantly strengthens BioNTech’s financial position.
"In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by strengthening the two pillars of our oncology strategy," said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech.
Despite the strong revenue performance, the company reaffirmed its full-year 2025 revenue guidance of €1.7-2.2 billion, below the consensus estimate of €2.27 billion. BioNTech expects revenue to be primarily concentrated in the last three to four months of the year.
The company maintained a robust financial position with €16.0 billion in cash and investments as of June 30, 2025. R&D expenses decreased 13% YoY to €509.1 million due to clinical trial reprioritization, reflecting the company’s focus on cost discipline while advancing its oncology pipeline.
BioNTech also received European Commission approval for its new variant-adapted COVID-19 vaccine, with deliveries expected to begin in August 2025. The company announced plans to acquire CureVac to strengthen its mRNA capabilities for cancer immunotherapies, further advancing its strategic transformation.
"While we continue to significantly invest into the execution of our strategy, our commitment to operational and financial discipline is starting to show tangible results," said Ramón Zapata, Chief Financial Officer at BioNTech.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.